Long-term disease control and survival observed after stereotactic ablative body radiotherapy for oligometastatic breast cancer.

Long-term systemic disease control and survival can be achieved with SABR for oligometastatic breast cancer. Hormone receptor-positive patients with a long disease interval from initial diagnosis and limited systemic progression history may be ideal for SABR to all sites of disease.